• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

筛选并验证 miR-1280 作为血清 microRNA 表达 qRT-PCR 分析的合适内参基因用于肝癌研究。

Selection and validation of miR-1280 as a suitable endogenous normalizer for qRT-PCR Analysis of serum microRNA expression in Hepatocellular Carcinoma.

机构信息

Fondazione Italiana Fegato - ONLUS, Liver Research Center, AREA Science Park, Basovizza, Trieste, Italy.

Universitas Hasanuddin, Faculty of Medicine, Makassar, Indonesia.

出版信息

Sci Rep. 2020 Feb 21;10(1):3128. doi: 10.1038/s41598-020-59682-0.

DOI:10.1038/s41598-020-59682-0
PMID:32081930
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7035418/
Abstract

Normalization procedures for the qRT-PCR analysis of miRNA in biological samples are recommended to reduce the variability caused by pre-analytical factors. Since there is no universal standardized normalization strategy for miRNA qRT-PCR studies, we conducted a throughout study to evaluate a panel of small non-coding RNAs (sncRNAs) as reference gene candidate for biomarker studies in serum samples of patients with hepatocellular carcinoma (HCC). Five sncRNAs (miR-1280, miR-1275, SNORD-116, SNORD-68, and U6) were chosen as candidate of reference genes. This study included 122 patients with HCC and was organized into a "pilot phase" consisting of 20 serum samples of HCC patients, and a "validation phase" of 102 patients. Expression level of these candidates were analyzed by qRT-PCR. Assessment of gene stability was performed using four different integrative platforms (geNorm NormFinder, Bestkeeper, and the Delta Ct method). To determine the gene stability during the follow-up of the patient, we extend the analysis of the validation cohort at T1 (1 month after treatment) and T2 (6 month after treatment). MiR-1280 was identified as the most stably expressed reference gene in both pilot and validation phase also during the follow-up. MiR-1280 appears a reliable reference gene candidate in biomarker studies.

摘要

建议对 miRNA 的 qRT-PCR 分析进行标准化处理,以减少由预分析因素引起的变异性。由于 miRNA qRT-PCR 研究没有通用的标准化标准化策略,我们进行了一项全面的研究,以评估一组小非编码 RNA(sncRNA)作为候选参考基因,用于肝癌(HCC)患者血清样本中的生物标志物研究。选择了 5 个 sncRNA(miR-1280、miR-1275、SNORD-116、SNORD-68 和 U6)作为候选参考基因。这项研究包括 122 名 HCC 患者,并分为“试点阶段”(由 20 名 HCC 患者的血清样本组成)和“验证阶段”(102 名患者)。通过 qRT-PCR 分析这些候选者的表达水平。使用四种不同的综合平台(geNorm NormFinder、Bestkeeper 和 Delta Ct 方法)评估基因稳定性。为了确定患者随访期间的基因稳定性,我们在 T1(治疗后 1 个月)和 T2(治疗后 6 个月)时扩展了验证队列的分析。miR-1280 在试点和验证阶段以及随访期间均被确定为最稳定的参考基因。miR-1280 似乎是生物标志物研究中可靠的参考基因候选物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/411b/7035418/85de9af65921/41598_2020_59682_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/411b/7035418/0879c5ee5fff/41598_2020_59682_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/411b/7035418/11813ad5a987/41598_2020_59682_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/411b/7035418/85de9af65921/41598_2020_59682_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/411b/7035418/0879c5ee5fff/41598_2020_59682_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/411b/7035418/11813ad5a987/41598_2020_59682_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/411b/7035418/85de9af65921/41598_2020_59682_Fig3_HTML.jpg

相似文献

1
Selection and validation of miR-1280 as a suitable endogenous normalizer for qRT-PCR Analysis of serum microRNA expression in Hepatocellular Carcinoma.筛选并验证 miR-1280 作为血清 microRNA 表达 qRT-PCR 分析的合适内参基因用于肝癌研究。
Sci Rep. 2020 Feb 21;10(1):3128. doi: 10.1038/s41598-020-59682-0.
2
Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies.肝癌切除研究中血清外泌体微小RNA表达分析内源性参考基因适用性的评估
Mol Med Rep. 2015 Sep;12(3):4683-4691. doi: 10.3892/mmr.2015.3919. Epub 2015 Jun 11.
3
Different normalization strategies might cause inconsistent variation in circulating microRNAs in patients with hepatocellular carcinoma.不同的标准化策略可能会导致肝细胞癌患者循环微RNA出现不一致的变化。
Med Sci Monit. 2015 Feb 26;21:617-24. doi: 10.12659/MSM.891028.
4
Identification and validation of miRNAs as endogenous controls for RQ-PCR in blood specimens for breast cancer studies.用于乳腺癌研究的血液样本中,作为实时定量聚合酶链反应内参的微小RNA的鉴定与验证
PLoS One. 2013 Dec 31;8(12):e83718. doi: 10.1371/journal.pone.0083718. eCollection 2013.
5
Circulating miRNA-199a and miRNA-122 Levels as Potential Diagnostic and Prognostic Biomarkers for Hepatocellular Carcinoma.循环 miRNA-199a 和 miRNA-122 水平作为肝细胞癌潜在的诊断和预后生物标志物。
Ann Clin Lab Sci. 2020 Mar;50(2):219-227.
6
Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection.血清 microRNAs 作为慢性乙型肝炎病毒感染中国患者肝细胞癌的生物标志物。
PLoS One. 2011;6(12):e28486. doi: 10.1371/journal.pone.0028486. Epub 2011 Dec 8.
7
Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation.早期循环微小RNA可预测肝细胞癌患者肝移植后的肿瘤复发及生存情况。
Oncotarget. 2016 Apr 12;7(15):19824-39. doi: 10.18632/oncotarget.7627.
8
Serum MicroRNAs as Biomarkers in Hepatitis C: Preliminary Evidence of a MicroRNA Panel for the Diagnosis of Hepatocellular Carcinoma.血清 microRNAs 作为丙型肝炎的生物标志物:microRNA 联合检测对肝细胞癌诊断的初步证据。
Int J Mol Sci. 2019 Feb 17;20(4):864. doi: 10.3390/ijms20040864.
9
Novel serum microRNAs panel on the diagnostic and prognostic implications of hepatocellular carcinoma.新型血清 microRNAs 标志物对肝细胞癌的诊断及预后意义。
World J Gastroenterol. 2018 Jun 28;24(24):2596-2604. doi: 10.3748/wjg.v24.i24.2596.
10
A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.血清 microRNA 分类器用于早期检测肝细胞癌:一项具有巢式病例对照研究的多中心、回顾性、纵向生物标志物识别研究。
Lancet Oncol. 2015 Jul;16(7):804-15. doi: 10.1016/S1470-2045(15)00048-0. Epub 2015 Jun 15.

引用本文的文献

1
Identification of Stable Housekeeping Genes for miRNA Expression Studies in a Mouse Unilateral Ureteral Obstruction Model.在小鼠单侧输尿管梗阻模型中用于miRNA表达研究的稳定管家基因的鉴定
Biochem Genet. 2025 Apr 17. doi: 10.1007/s10528-025-11105-3.
2
Integrated analysis of long non‑coding RNA megacluster, microRNA‑132 and microRNA‑133a and their implications for cardiovascular risk and kidney failure progression in diabetic patients.长链非编码RNA巨簇、微小RNA-132和微小RNA-133a的综合分析及其对糖尿病患者心血管风险和肾衰竭进展的影响
Exp Ther Med. 2024 Dec 18;29(2):35. doi: 10.3892/etm.2024.12785. eCollection 2025 Feb.
3

本文引用的文献

1
A comparative characterization of the circulating miRNome in whole blood and serum of HCC patients.比较分析 HCC 患者全血和血清中循环 miRNA 组特征。
Sci Rep. 2019 Jun 4;9(1):8265. doi: 10.1038/s41598-019-44580-x.
2
Circulating microRNA-1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma.循环微RNA-1246作为肝细胞癌早期肿瘤复发的一种可能生物标志物。
Hepatol Res. 2019 Jul;49(7):810-822. doi: 10.1111/hepr.13338. Epub 2019 May 23.
3
RNU6B, a frequent reference in miRNA expression studies, differentiates between deaths caused by hypothermia and chronic cardiac ischemia.
Two-step formulation of magnetic nanoprobes for microRNA capture.
用于捕获微小RNA的磁性纳米探针的两步法制备
RSC Adv. 2022 Mar 2;12(12):7179-7188. doi: 10.1039/d1ra09016j. eCollection 2022 Mar 1.
4
The role of microRNA-4723-5p regulated by c-myc in triple-negative breast cancer.c-myc 调控的 microRNA-4723-5p 在三阴性乳腺癌中的作用。
Bioengineered. 2022 Apr;13(4):9097-9105. doi: 10.1080/21655979.2022.2056824.
5
Weighted miRNA co-expression networks analysis identifies circulating miRNA predicting overall survival in hepatocellular carcinoma patients.加权 miRNA 共表达网络分析鉴定出可预测肝细胞癌患者总生存期的循环 miRNA。
Sci Rep. 2020 Nov 3;10(1):18967. doi: 10.1038/s41598-020-75945-2.
6
Identification of miR-4644 as a suitable endogenous normalizer for circulating miRNA quantification in hepatocellular carcinoma.鉴定miR-4644作为肝细胞癌循环miRNA定量的合适内源性标准化物。
J Cancer. 2020 Oct 17;11(23):7032-7044. doi: 10.7150/jca.48903. eCollection 2020.
7
Fecal microRNAs as Innovative Biomarkers of Intestinal Diseases and Effective Players in Host-Microbiome Interactions.粪便微小RNA作为肠道疾病的创新生物标志物及宿主-微生物组相互作用的有效参与者。
Cancers (Basel). 2020 Aug 5;12(8):2174. doi: 10.3390/cancers12082174.
RNU6B是miRNA表达研究中常用的参照,可区分低温和慢性心脏缺血导致的死亡。
Int J Legal Med. 2020 Jan;134(1):159-162. doi: 10.1007/s00414-019-02041-0. Epub 2019 Mar 23.
4
Relative and Absolute Expression Analysis of MicroRNAs Associated with Luminal A Breast Cancer- A Comparison.与腔面A型乳腺癌相关的微小RNA的相对和绝对表达分析——一项比较研究
Pathol Oncol Res. 2020 Apr;26(2):833-844. doi: 10.1007/s12253-019-00627-y. Epub 2019 Mar 6.
5
The circulating miRNAs as diagnostic and prognostic markers.循环 miRNA 作为诊断和预后标志物。
Clin Chem Lab Med. 2019 Jun 26;57(7):932-953. doi: 10.1515/cclm-2018-0838.
6
The crucial need of internal control validation in the normalization of circulating microRNAs.循环微RNA标准化中内部控制验证的关键需求。
Dig Liver Dis. 2019 Apr;51(4):610-611. doi: 10.1016/j.dld.2019.01.009. Epub 2019 Feb 7.
7
Serum levels of candidate microRNA diagnostic markers differ among the stages of non-small-cell lung cancer.候选微小RNA诊断标志物的血清水平在非小细胞肺癌各阶段有所不同。
Oncol Lett. 2018 Nov;16(5):6643-6651. doi: 10.3892/ol.2018.9464. Epub 2018 Sep 20.
8
Systemic treatment for hepatocellular carcinoma.肝细胞癌的全身治疗
Chronic Dis Transl Med. 2018 Sep 17;4(3):148-155. doi: 10.1016/j.cdtm.2018.08.003. eCollection 2018 Sep.
9
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
10
Impact of miRNA-mRNA Profiling and Their Correlation on Medulloblastoma Tumorigenesis.微小RNA-信使核糖核酸谱分析及其相关性对髓母细胞瘤肿瘤发生的影响
Mol Ther Nucleic Acids. 2018 Sep 7;12:490-503. doi: 10.1016/j.omtn.2018.06.004. Epub 2018 Jun 19.